Close Menu

Proteomics & Protein Research

News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.

The company's BAMS technology combines immuno-enrichment of protein targets with MALDI to enable rapid, multiplexed analysis of proteins and proteoforms.

Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.

The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.

Under the agreements, Bioké, a business unit of Cell Signaling Technology Europe, will distribute the two platforms in the Netherlands, Belgium, and Luxembourg.

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

In Nature this week: a new method for high-throughput amplicon sequencing, and more.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.